Crestone Inc., founded in Boulder, Colorado, is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates with unique mechanisms to combat serious bacterial infections. The company's core mission is to break the cycle of bacterial growth and resistance, addressing critical healthcare needs. Crestone's research pipeline includes treatments for C. difficile, antibiotic-resistant Gram-positive infections, and Tuberculosis, among other serious bacterial diseases.
Notable affiliated individuals and investors include experienced scientists and industry veterans who drive the company's innovative research and development efforts. Crestone has achieved significant milestones in advancing its drug candidates through various stages of clinical trials, demonstrating promising efficacy and safety profiles. The company's impact lies in its potential to revolutionize the treatment of bacterial infections, offering new hope in the fight against antibiotic resistance.
